Targeted drug delivery to melanoma.
暂无分享,去创建一个
Leaf Huang | Leaf Huang | Qi Liu | Manisit Das | Yun Liu | Qi Liu | Manisit Das | Yun Liu
[1] Erik Sahai,et al. Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling , 2015, Cancer cell.
[2] V. Gotlieb,et al. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond. , 2016, Critical reviews in oncology/hematology.
[3] J. Hansson,et al. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site , 2008, Molecular oncology.
[4] Sarat Chandarlapaty,et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. , 2011, Cancer discovery.
[5] F. Huang,et al. Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro , 2009, International journal of cancer.
[6] Jiwei Cui,et al. Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery. , 2017, ACS nano.
[7] G. Robertson,et al. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. , 2010, Biochemical pharmacology.
[8] Genevieve M. Boland,et al. Melanoma: Advances in Targeted Therapy and Molecular Markers , 2015, Annals of Surgical Oncology.
[9] A. Sasse,et al. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. , 2007, The Cochrane database of systematic reviews.
[10] H. Ananthaswamy,et al. Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines , 2004, Oncogene.
[11] Quanyin Hu,et al. Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors. , 2016, ACS nano.
[12] C. Ciccarelli,et al. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors , 2006, Molecular Cancer.
[13] Michael Riediker,et al. Therapeutic nanoparticles in clinics and under clinical evaluation. , 2013, Nanomedicine.
[14] K. Flaherty,et al. Meeting report: The future of preclinical mouse models in melanoma treatment is now , 2013, Pigment cell & melanoma research.
[15] Xiaoyuan Chen,et al. Tumor Vasculature Targeted Photodynamic Therapy for Enhanced Delivery of Nanoparticles , 2014, ACS nano.
[16] Spitler Le. Letter: The use of the cell migration inhibition test. , 1974 .
[17] D. Schadendorf,et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] E. Van Cutsem,et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] O. Podhajcer,et al. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. , 1997, The Journal of investigative dermatology.
[20] William Y. Kim,et al. Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors. , 2017, Cancer research.
[21] M. Atkins,et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] G. Merlino,et al. From UVs to metastases: modeling melanoma initiation and progression in the mouse. , 2008, The Journal of investigative dermatology.
[23] D. Bar-Sagi,et al. The structural basis for the transition from Ras-GTP to Ras-GDP , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[24] D. Trump,et al. A phase II study of taxol in patients with malignant melanoma , 1991, Investigational New Drugs.
[25] Leaf Huang,et al. Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. , 2017, ACS nano.
[26] M. Gordon. Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis , 2010 .
[27] Nathan Johnston,et al. Non-covalently functionalized single-walled carbon nanotube for topical siRNA delivery into melanoma. , 2014, Biomaterials.
[28] M. Mason,et al. Systemic treatments for metastatic cutaneous melanoma. , 2000, The Cochrane database of systematic reviews.
[29] R. Dummer,et al. Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma , 2011, Clinical Cancer Research.
[30] N Cascinelli,et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] T. Vermonden,et al. Strong in vivo antitumor responses induced by an antigen immobilized in nanogels via reducible bonds. , 2016, Nanoscale.
[32] H. Schreiber,et al. Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.
[33] K. Flaherty,et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] A. Kissenpfennig,et al. Microneedle-mediated vaccine delivery: Harnessing cutaneous immunobiology to improve efficacy , 2012, Expert opinion on drug delivery.
[35] A. Jemal,et al. Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.
[36] F. Buonaguro,et al. Antigen-specific vaccines for cancer treatment , 2014, Human vaccines & immunotherapeutics.
[37] J. Wilmott,et al. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients , 2015, Clinical Cancer Research.
[38] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[39] D. Schadendorf,et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] R. DePinho,et al. BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.
[41] Suk Woo Nam,et al. BRAF and KRAS mutations in stomach cancer , 2003, Oncogene.
[42] Zhen Gu,et al. Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody. , 2016, Nano letters.
[43] M. Weichenthal,et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] Leaf Huang,et al. Lipid-based vectors for siRNA delivery , 2012, Journal of drug targeting.
[45] A. Daud,et al. Plasmid IL-12 electroporation in melanoma , 2012, Human vaccines & immunotherapeutics.
[46] G. Linette,et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.
[47] Leaf Huang,et al. Surface‐Modified LPD Nanoparticles for Tumor Targeting , 2006, Annals of the New York Academy of Sciences.
[48] K. Nielsen,et al. The clinical significance of BRAF and NRAS mutations in a clinic‐based metastatic melanoma cohort , 2013, The British journal of dermatology.
[49] J. Becker,et al. Mouse models for melanoma: a personal perspective , 2010, Experimental dermatology.
[50] Suzie Chen,et al. Genetics of melanoma , 2013, Front. Gene..
[51] B. Lu,et al. T-cell death and cancer immune tolerance , 2008, Cell Death and Differentiation.
[52] Yuhua Wang,et al. Nanoparticle-Delivered Transforming Growth Factor-β siRNA Enhances Vaccination against Advanced Melanoma by Modifying Tumor Microenvironment , 2014, ACS nano.
[53] A. Bucheit,et al. Emerging insights into resistance to BRAF inhibitors in melanoma. , 2014, Biochemical pharmacology.
[54] B. Ruggeri,et al. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. , 2014, Biochemical pharmacology.
[55] S. Rosenberg,et al. Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.
[56] I. Melero,et al. Therapeutic vaccines for cancer: an overview of clinical trials , 2014, Nature Reviews Clinical Oncology.
[57] S. D. De Smedt,et al. Ultradeformable cationic liposomes for delivery of small interfering RNA (siRNA) into human primary melanocytes. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[58] E. Miyaji,et al. Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants. , 2011, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[59] Probal Banerjee,et al. Responsive polymer-fluorescent carbon nanoparticle hybrid nanogels for optical temperature sensing, near-infrared light-responsive drug release, and tumor cell imaging. , 2014, Nanoscale.
[60] C. Blank,et al. Targeting BRAFV600E in an inducible murine model of melanoma. , 2012, The American journal of pathology.
[61] Yuhua Wang,et al. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach. , 2016, Cancer letters.
[62] M. N. Epstein,et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. , 1984, Human pathology.
[63] G. Linette,et al. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104) , 2012, Journal of Translational Medicine.
[64] G. Saldanha,et al. High BRAF mutation frequency does not characterize all melanocytic tumor types , 2004, International journal of cancer.
[65] A. Aruga,et al. Immunological monitoring of anticancer vaccines in clinical trials , 2013, Oncoimmunology.
[66] Ryan F. Donnelly,et al. Skin Dendritic Cell Targeting via Microneedle Arrays Laden with Antigen-Encapsulated Poly-d,l-lactide-co-Glycolide Nanoparticles Induces Efficient Antitumor and Antiviral Immune Responses , 2013, ACS nano.
[67] C. Warneke,et al. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. , 2006, The Journal of investigative dermatology.
[68] P. Lorigan,et al. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] R. Marais,et al. Melanoma biology and new targeted therapy , 2007, Nature.
[70] A. Jemal,et al. Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[71] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[72] M. Herlyn. Human melanoma: Development and progression , 1990, Cancer and Metastasis Reviews.
[73] J. Hassel. Ipilimumab plus nivolumab for advanced melanoma. , 2016, The Lancet. Oncology.
[74] Chao Wang,et al. Local delivery of checkpoints antibodies , 2017, Human vaccines & immunotherapeutics.
[75] G. Pupo,et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma , 2014, Molecular oncology.
[76] Özlem Türeci,et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.
[77] Richard Heller,et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] J. Eberle,et al. Expression and Function of Bcl-2 Proteins in Melanoma , 2008, Current genomics.
[79] Yuhua Wang,et al. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[80] Xianglin Shi,et al. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. , 2003, Biochemical and biophysical research communications.
[81] R. Heller,et al. Delivery of Interleukin-15 to B16 Melanoma by Electroporation Leads to Tumor Regression and Long-term Survival , 2014, Technology in cancer research & treatment.
[82] M. Gulley,et al. BRAF mutation testing in colorectal cancer. , 2010, Archives of pathology & laboratory medicine.
[83] Chao Zhang,et al. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.
[84] S. Rosenberg,et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.
[85] Tamer Refaat,et al. Cancer active targeting by nanoparticles: a comprehensive review of literature , 2015, Journal of Cancer Research and Clinical Oncology.
[86] Dennis C. Friedrich,et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.
[87] P. Ladenson,et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. , 2005, The Journal of clinical endocrinology and metabolism.
[88] A. Robins. Biological Perspectives on Human Pigmentation , 1991 .
[89] J. Wolchok,et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. , 2013, The New England journal of medicine.
[90] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[91] H. Pehamberger,et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] S. Aamdal,et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. , 1994, European journal of cancer.
[93] B. Peterson,et al. Vindesine for metastatic malignant melanoma. A phase II trial. , 1983, American Journal of Clinical Oncology.
[94] Probal Banerjee,et al. Core-shell hybrid nanogels for integration of optical temperature-sensing, targeted tumor cell imaging, and combined chemo-photothermal treatment. , 2010, Biomaterials.
[95] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.
[96] B. Beutler,et al. Type I interferons (alpha/beta) in immunity and autoimmunity. , 2005, Annual review of immunology.
[97] P. Linsley,et al. CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.
[98] G. Pupo,et al. BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact , 2014, Clinical Cancer Research.
[99] Kwangmeyung Kim,et al. Engineered Human Ferritin Nanoparticles for Direct Delivery of Tumor Antigens to Lymph Node and Cancer Immunotherapy , 2016, Scientific Reports.
[100] Hugh M Gloster,et al. Skin cancer in skin of color. , 2006, Journal of the American Academy of Dermatology.
[101] J. Wolchok,et al. Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo , 2015, The Journal of Immunology.
[102] M. Suarez‐Almazor,et al. Review: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer , 2017, Arthritis & rheumatology.
[103] S. Rosenberg,et al. Adoptive cell therapy for the treatment of patients with metastatic melanoma. , 2009, Current opinion in immunology.
[104] I. Fidler,et al. Cancer metastasis. , 1991, British medical bulletin.
[105] J. Schneck,et al. Adoptive T Cell Immunotherapy for Cancer , 2015, Rambam Maimonides medical journal.
[106] B. Lang,et al. Immune checkpoint inhibitors: a milestone in the treatment of melanoma , 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[107] L. Flaherty,et al. Treatment of metastatic malignant melanoma , 2005, Current treatment options in oncology.
[108] Yuhua Wang,et al. Co-delivery of Cisplatin and Rapamycin for Enhanced Anticancer Therapy through Synergistic Effects and Microenvironment Modulation , 2014, ACS nano.
[109] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .
[110] Zheng Gai,et al. Multi-functional core-shell hybrid nanogels for pH-dependent magnetic manipulation, fluorescent pH-sensing, and drug delivery. , 2011, Biomaterials.
[111] D. Lev,et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] Marie-Hélène Dufresne,et al. Block copolymer micelles: preparation, characterization and application in drug delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[113] J. Cheng,et al. Deregulated Akt3 Activity Promotes Development of Malignant Melanoma , 2004, Cancer Research.
[114] Jung-Hwan Park,et al. Microneedles for drug and vaccine delivery. , 2012, Advanced drug delivery reviews.
[115] R. Ralhan,et al. Angiogenesis in cutaneous melanoma: Pathogenesis and clinical implications , 2003, Microscopy research and technique.
[116] I. Riemann,et al. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. , 2010, Biomaterials.
[117] M. Gordon. In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling , 2008 .
[118] Probal Banerjee,et al. Magnetic/NIR-thermally responsive hybrid nanogels for optical temperature sensing, tumor cell imaging and triggered drug release. , 2014, Nanoscale.
[119] Leaf Huang,et al. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[120] Youssef W. Naguib,et al. The effect of microneedles on the skin permeability and antitumor activity of topical 5-fluorouracil , 2014, Acta pharmaceutica Sinica. B.
[121] J. Allison,et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.
[122] N. Sharpless,et al. Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors. , 2012, The oncologist.
[123] Kun-Liang Guan,et al. Mechanisms of regulating the Raf kinase family. , 2003, Cellular signalling.
[124] Rebecca L. Siegel Mph,et al. Cancer statistics, 2016 , 2016 .
[125] A. Olszanski. Current and Future Roles of Targeted Therapy and Immunotherapy in Advanced Melanoma , 2014, Journal of managed care & specialty pharmacy.
[126] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[127] S. Geary,et al. Nanoparticle Delivery Systems in Cancer Vaccines , 2011, Pharmaceutical Research.
[128] David Polsky,et al. Focus on melanoma. , 2002, Cancer cell.
[129] M. Herlyn,et al. What is a good model for melanoma? , 2010, The Journal of investigative dermatology.
[130] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[131] D. Morton,et al. Therapeutic Vaccines for Melanoma , 2012, BioDrugs.
[132] M. Chougule,et al. Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging. , 2015, Journal of biomedical nanotechnology.
[133] K. Hunter,et al. Modeling metastasis in vivo. , 2004, Carcinogenesis.
[134] A. Aplin,et al. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. , 2010, Cancer research.
[135] E. Maiello,et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study , 2003, Melanoma research.
[136] Yuhua Wang,et al. Curcumin Micelles Remodel Tumor Microenvironment and Enhance Vaccine Activity in an Advanced Melanoma Model. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[137] L. Old,et al. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? , 1984, Nature.
[138] W. Scheithauer,et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[139] L. Chin,et al. Genetics and genomics of melanoma. , 2009, Expert review of dermatology.
[140] R. Sullivan,et al. Resistance to BRAF-targeted therapy in melanoma. , 2013, European journal of cancer.
[141] M. Brewster,et al. Prediction of drug solubility in amphiphilic di-block copolymer micelles: the role of polymer-drug compatibility. , 2007, Die Pharmazie.
[142] H. Tsao,et al. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. , 2008, The Journal of investigative dermatology.
[143] David L Porter,et al. Chimeric antigen receptor therapy for cancer. , 2014, Annual review of medicine.
[144] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[145] S. W. Kim,et al. Arginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNA. , 2012, Biomaterials.
[146] Zhaocai Zhou,et al. Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy. , 2016, Nano letters.
[147] S. Lowe,et al. Apoptosis and melanoma chemoresistance , 2003, Oncogene.
[148] Richard Heller,et al. Electroporation gene therapy preclinical and clinical trials for melanoma. , 2010, Current gene therapy.
[149] B. Nilius,et al. Pharmacology of Vanilloid Transient Receptor Potential Cation Channels , 2009, Molecular Pharmacology.
[150] Shutao Guo,et al. Nanoformulations for combination or cascade anticancer therapy. , 2017, Advanced drug delivery reviews.
[151] D. Peeper,et al. BRAFE600 in benign and malignant human tumours , 2008, Oncogene.
[152] Dirk Schadendorf,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[153] B. Beutler,et al. TYPE I INTERFERONS (/) IN IMMUNITY AND AUTOIMMUNITY , 2005 .
[154] Bozena Michniak-Kohn,et al. Development of edge-activated liposomes for siRNA delivery to human basal epidermis for melanoma therapy. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[155] G. Robertson,et al. Is B-Raf a good therapeutic target for melanoma and other malignancies? , 2008, Cancer research.
[156] X. Qian,et al. Transdermal delivery of the in situ hydrogels of curcumin and its inclusion complexes of hydroxypropyl-β-cyclodextrin for melanoma treatment. , 2014, International journal of pharmaceutics.
[157] Leaf Huang,et al. Quercetin Remodels the Tumor Microenvironment To Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles. , 2017, ACS nano.
[158] T. Eberlein. Durable Complete Responses in Heavily Pretreated Patients with metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2012 .
[159] R. McWilliams,et al. A randomized phase 2 study of temozolomide and bevacizumab or nab‐paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma , 2013, Cancer.
[160] V. Suman,et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma , 2009, Cancer.
[161] S. Mitragotri,et al. Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.
[162] A. Jemal,et al. Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[163] Kinam Park,et al. Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle–cell interaction , 2010, Expert opinion on drug delivery.
[164] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[165] S. Woodman,et al. Role and therapeutic potential of PI3K‐mTOR signaling in de novo resistance to BRAF inhibition , 2012, Pigment cell & melanoma research.
[166] J. Utikal,et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.
[167] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[168] A. Bagg,et al. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. , 2015, The New England journal of medicine.
[169] F. Aubin,et al. [Melanoma: role of ultraviolet radiation: from physiology to pathology]. , 2001, Presse medicale.
[170] J. Kirkwood,et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. , 2014, JAMA.
[171] Jane Fridlyand,et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.
[172] M. Herlyn,et al. Molecular biology of human melanoma development and progression , 1998, Molecular carcinogenesis.
[173] I. Fidler,et al. Murine models to evaluate novel and conventional therapeutic strategies for cancer. , 2007, The American journal of pathology.
[174] Murad Alam,et al. The use of brachytherapy in the treatment of nonmelanoma skin cancer: a review. , 2011, Journal of the American Academy of Dermatology.
[175] K. Flaherty,et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[176] C. Grin,et al. Accuracy in the clinical diagnosis of malignant melanoma. , 1990, Archives of dermatology.
[177] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[178] J. Lomas,et al. The genetics of malignant melanoma. , 2008, Frontiers in bioscience : a journal and virtual library.
[179] F. Liu,et al. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[180] S. Holmen,et al. Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma , 2011, Chinese journal of cancer.
[181] Nikolas K. Haass,et al. Modeling Melanoma In Vitro and In Vivo , 2013, Healthcare.
[182] Pierre Hubert,et al. Tyrosine kinase receptors as attractive targets of cancer therapy. , 2004, Critical reviews in oncology/hematology.
[183] Wei Liu,et al. Transgenic mouse model for skin malignant melanoma , 1998, Oncogene.
[184] Ram I Mahato,et al. Nanoparticle-mediated drug delivery for treating melanoma. , 2015, Nanomedicine.
[185] T. Janowitz,et al. Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008 , 2014, Drug design, development and therapy.
[186] Mark R Prausnitz,et al. Microneedles for transdermal drug delivery. , 2004, Advanced drug delivery reviews.
[187] Damien Kee,et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.
[188] J. Wisell,et al. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma , 2013 .
[189] Yuhua Wang,et al. Tumor‐targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[190] A. Doherty,et al. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. , 1997, The Journal of pharmacology and experimental therapeutics.
[191] Probal Banerjee,et al. Chitosan-based responsive hybrid nanogels for integration of optical pH-sensing, tumor cell imaging and controlled drug delivery. , 2010, Biomaterials.
[192] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[193] L. Arnaut,et al. Design of Pluronic-Based Formulation for Enhanced Redaporfin-Photodynamic Therapy against Pigmented Melanoma. , 2016, ACS applied materials & interfaces.
[194] T. Eberlein. gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma , 2012 .
[195] R. Marchessault,et al. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[196] Sarat Chandarlapaty,et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. , 2011, Cancer cell.
[197] J. Stewart,et al. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686) , 2003, Melanoma research.
[198] C. Garbe,et al. Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low–normal serum lactate dehydrogenase: ‘The AGENDA trial’ , 2014, Melanoma research.
[199] A. Ribas,et al. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[200] Y. Miyahara,et al. Phenylboronic acid-installed polymeric micelles for targeting sialylated epitopes in solid tumors. , 2013, Journal of the American Chemical Society.
[201] Ana C Anderson,et al. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.
[202] B. Youan,et al. Engineering nanomedicines for improved melanoma therapy: progress and promises. , 2010, Nanomedicine.
[203] D. Brodland,et al. The Epidemiology of Skin Cancer , 1996, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].